Physician profile
John P Davis
NPI 1588608483
$1,746.80
in general payments reported to CMS, 2019-2025
18 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.46 · 2020: $14.00 · 2021: $139 · 2022: $16.68 · 2023: $72.40 · 2024: $362 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $419.60 | 2024-2025 | |
| Dexcom, INC. | $223.66 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Novo Nordisk INC | $208.47 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $164.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $154.96 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $106.18 | 2019-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Amgen INC. | $82.15 | 2024-2025 | Evenity, Prolia, Krystexxa |
| Philips North America LLC | $74.72 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Exact Sciences Corporation | $56.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $43.49 | 2023-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $40.54 | 2025 | |
| Medtronic, INC. | $39.96 | 2024 | Gi Genius |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.12 | 2021-2022 | |
| Boston Scientific Corporation | $27.26 | 2025 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $24.82 | 2025 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.53 | 2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $13.70 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.